Factors Associated with Mortality among Patients on TB Treatment in the Southern Region of Zimbabwe, 2013
Table 2
Clinical characteristics of TB patients in southern Zimbabwe, 2013.
Characteristics
Percentage (95% CI)
TB category
New
1,653
1,969
84.0 (82.3–85.5)
Retreatment
314
1,969
15.9 (14.4–17.6)
MDR-TB
2
1,969
0.1 (0.0–0.4)
Missing data
2
1,971
0.1
Type of new TB
Smear-positive PTB
603
1,651
36.5 (34.2–38.9)
Smear-negative PTB
720
1,651
43.6 (41.2–46.0)
EPTB
227
1,651
13.7 (12.2–15.5)
Smear-not-performed PTB
101
1,651
6.1 (5.1–7.4)
Missing
2
1,653
0.12
Type of retreatment TB
Treatment after default
29
308
9.4 (6.6–13.2)
Retreatment others
191
308
62.0 (56.4–67.3)
Relapse
78
308
25.3 (20.8–30.5)
Treatment after failure
10
308
3.2 (1.7–5.9)
Missing data
6
314
1.9
HIV status
HIV-negative
419
1,971
21.3 (19.5–23.1)
HIV-positive
1,538
1,971
78.0 (76.1–79.8)
Unknown
14
1,971
0.7 (0.4–1.2)
WHO clinical staging at ART
I
30
638
4.7 (3.3–6.7)
II
75
638
11.8 (9.5–14.5)
III
494
638
77.4 (74.0–80.5)
IV
39
638
6.1 (4.5–8.3)
Missing data
900
1,538
58.5
CD4 count (cells/mL) at ART
≤50
96
364
26.4 (22.1–31.2)
51–200
137
364
37.6 (32.8–42.8)
201–350
74
364
20.3 (16.5–24.8)
351–500
28
364
7.7 (5.4–10.9)
>500
29
364
8.0 (5.6–11.2)
Missing data
1,174
1,538
76.3
Median (IQR)
132.5 (46; 282)
ART use
No
139
1,538
9.0 (7.7–10.6)
Yes
1,399
1,538
91.0 (89.4–92.3)
ART initiation in relation to start of TB
>3 months before TB treatment
412
1,399
29.4 (27.1–31.9)
0–3 months before TB treatment
172
1,399
12.3 (10.7–14.1)
<2 weeks after TB treatment
543
1,399
38.8 (36.3–41.4)
2–8 weeks after TB treatment
15
1,399
1.1 (0.6–1.8)
Not recorded
257
1,399
18.4 (16.4–20.5)
CI = confidence interval; TB = tuberculosis; MDR-TB = multidrug resistant TB; PTB = pulmonary TB; EPTB = extrapulmonary PTB; HIV = human immunodeficiency virus; WHO = World Health Organisation; IQR = interquartile range; ART = antiretroviral therapy. variables refer only to those who were diagnosed as HIV-positive.